YAP1 and hepatocellular carcinoma: To investigate whether Roblitinib and CPI-169 synergistically inhibit HCC development in a YAP signaling-dependent manner, a YAP1 mutant construct YAP1S127A, which stimulates YAP1 binding to TEAD1, was stably transfected into HepG2 and SMMC-7721 cell lines (Fig. 6A).